Annals of Surgery

Our medical research library holds 7 studies published in Annals of Surgery (1948–2026). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 5 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Lippincott Williams & Wilkins
• Published: 1885 to the present, United States
• Language: English
• ISSN: 0003-4932 (print), 1528-1140 (electronic)
• Its record in the NLM Catalog

2020s

• Recurrence Patterns and Management after Pleurectomy Decortication for Pleural Mesothelioma. J. Paajanen, W.G. Richards, Y. Xie, et al. 2026;283(5):734-742. PubMed · Publisher · Free full text

  Abstract

  Objective: To hypothesize that recurrence after pleurectomy decortication is primarily local. We explored factors associated with tumor recurrence patterns, disease-free interval, and postrecurrence survival (PRS).

  Background: Tumor recurrence is a major barrier to long-term survival after pleural mesothelioma (PM) surgery.

  Methods: All patients who underwent pleurectomy decortication between 1998 and 2022 were identified. Patients with diffuse PM who achieved macroscopic complete resection and had sufficient information on tumor relapse were included. Postoperative scans were reviewed to determine the timing and sites of the first recurrence.

  Results: A total of 436 patients had tumor recurrence during follow-up. Local recurrences occurred most frequently (N = 370, 85%) and represented the only recurrence site in 29% (N = 129) of cases. Patients with sarcomatoid tumors relapsed earlier than other subtypes ( P = 0.003) with more frequent distant spread compared with other subtypes ( P < 0.001). Multivariable analysis revealed that age ( P = 0.015), preoperative tumor volume ( P < 0.001), epithelioid histology ( P < 0.001), intraoperative chemotherapy ( P < 0.001), and TNM stage IV ( P = 0.003) were associated with disease-free interval. Similarly, age ( P = 0.042), performance status ( P < 0.001), epithelioid histology ( P < 0.001), intraoperative chemotherapy ( P < 0.001), TNM stages III and IV ( P = 0.003 and 0.010, respectively), type of surgery ( P = 0.019), and number of recurrent lesions ( P = 0.024) were associated with PRS. Recurrence surgery (hazard ratio: 0.46, 95% CI: 0.29-0.74) and chemotherapy (hazard ratio: 0.69, 95% CI: 0.54-0.92) were independently associated with PRS in patients with distant with or without local recurrences.

  Conclusions: PM is frequently associated with local recurrence. Repeat surgical resection is feasible and can achieve good local control in selected cases.

  Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.

• A Prospective Clinical Trial to Evaluate Mesothelin as a Biomarker for the Clinical Management of Patients With Esophageal Adenocarcinoma. A.J. Byun, R.A. Grosser, J.K. Choe, et al. 2023;278(5):e1003-e1010. PubMed · Publisher · Free full text

  Abstract

  Objective: To investigate the utility of serum soluble mesothelin-related peptide (SMRP) and tumor mesothelin expression in the management of esophageal adenocarcinoma (ADC).

  Background: Clinical management of esophageal ADC is limited by a lack of accurate evaluation of tumor burden, treatment response, and disease recurrence. Our retrospective data showed that tumor mesothelin and its serum correlate, SMRP, are overexpressed and associated with poor outcomes in patients with esophageal ADC.

  Methods: Serum SMRP and tumoral mesothelin expression from 101 patients with locally advanced esophageal ADC were analyzed before induction chemoradiation (pretreatment) and at the time of resection (posttreatment), as a biomarker for treatment response, disease recurrence, and overall survival (OS).

  Results: Pre and posttreatment serum SMRP was ≥1 nM in 49% and 53%, and pre and post-treatment tumor mesothelin expression was >25% in 35% and 46% of patients, respectively. Pretreatment serum SMRP was not significantly associated with tumor stage ( P = 0.9), treatment response (radiologic response, P = 0.4; pathologic response, P = 0.7), or recurrence ( P =0.229). Pretreatment tumor mesothelin expression was associated with OS (hazard ratio: 2.08; 95% CI: 1.14-3.79; P = 0.017) but had no statistically significant association with recurrence ( P = 0.9). Three-year OS of patients with pretreatment tumor mesothelin expression of ≤25% was 78% (95% CI: 68%-89%), compared with 49% (95% CI: 35%-70%) among those with >25%.

  Conclusions: Pretreatment tumor mesothelin expression is prognostic of OS for patients with locally advanced esophageal ADC, whereas serum SMRP is not a reliable biomarker for monitoring treatment response or recurrence.

  Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

2010s

• Extrapleural Pneumonectomy Is Not Shown to Be Clinically Effective in the Treatment of Malignant Pleural Mesothelioma. G. Cardillo, T. Treasure. 2017;265(4):e53. Letter PubMed · Publisher

• Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. D.J. Sugarbaker, W.G. Richards, R. Bueno. 2014;260(4):577-80; discussion 580-2. PubMed · Publisher · Free full text

  Abstract

  Objective: We review our 24-year experience with extrapleural pneumonectomy (EPP) in the treatment of epithelioid malignant pleural mesothelioma (MPM).

  Background: Recent publications, particularly the MARS (Mesothelioma and Radical Surgery) feasibility study by Treasure et al, have questioned the safety and efficacy of EPP for MPM.

  Methods: An institutional review board-approved, prospective, single-center database was retrospectively reviewed. Descriptive statistics and Kaplan-Meier analysis of overall survival are reported.

  Results: From 1988 to 2011, a total of 529 patients with epithelioid MPM underwent complete resection by EPP as part of a multimodality strategy. Among these, 131 (25%) were women, and the median age was 59 (range, 17-79) years. Median postoperative hospital stay was 10 (range, 1-101) days. Twenty-six patients (5%) experienced 30-day or in-hospital mortality. Median overall survival was 18 months, with 1-, 3-, 5-, and 10-year survival rates of 67%, 28%, 14%, and 4%, respectively. Outcome by pathologic lymph node status (N, median overall survival) was N0: 224, 26 months; N1: 118, 17 months; N2: 181, 13 months; N3: 5, 7 months; Nx: 1, not evaluable.

  Conclusions: EPP has evolved as an effective method for macroscopic complete resection. This study confirms that lymph node status is significantly correlated with overall survival in patients with epithelioid MPM undergoing EPP and suggests that those with simultaneous involvement of N1 and N2 stations are at increased risk. This observation underscores the need for thorough staging of both N1 and N2 stations and has implications for revision of MPM staging criteria.

• Pretreatment serum C-reactive protein levels predict benefit from multimodality treatment including radical surgery in malignant pleural mesothelioma: a retrospective multicenter analysis. B. Ghanim, M.A. Hoda, M.P. Winter, et al. 2012;256(2):357-62. PubMed · Publisher

  Abstract

  Objective: To evaluate the prognostic and predictive relevance of pretreatment serum C-reactive protein (CRP) in malignant pleural mesothelioma (MPM) patients.

  Background: MPM is a rare but aggressive disease with poor treatment outcome. Therapeutic decision is challenging, and predictive biomarkers for better treatment stratification are urgently needed.

  Methods: Clinical data, including survival and pretreatment CRP levels, were retrospectively collected from 115 patients with histologically proven MPM. Patients with any evidence for infectious disease were excluded. The association between CRP levels and survival was analyzed using Cox models adjusted for clinical and pathological factors.

  Results: Median pretreatment CRP of all patients was 1.19 mg/dL (range: 0.00-22.62 mg/dL). Patients with elevated CRP levels (≥1 mg/dL; n = 62, 53.9%) had a significantly shorter overall survival compared with those with normal CRP (hazard ratio [HR] 2.81, 95% confidence interval [CI] 1.82-4.33; P < 0.001). In multivariate survival analyses, elevated CRP was confirmed as an independent prognostic factor in MPM (HR 2.07, 95% CI 1.23-3.46; P = 0.01). Most interestingly, we observed a significant interaction between CRP and treatment modality (P < 0.001). Among patients with normal CRP levels, radical tumor resection within multimodality therapy was associated with distinctly prolonged overall survival when compared with treatment protocols without surgery (HR 7.26, 95% CI 3.40-15.49; P < 0.001). In contrast among patients with elevated CRP, no survival benefit was achieved by radical surgery within multimodality approaches (HR 0.911, 95% CI 0.53-1.58; P = 0.74).

  Conclusions: Our results suggest that multimodality regimens including radical resection increase survival selectively in MPM patients with normal pretreatment serum CRP levels.

• Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program. T.C. Chua, S. Martin, A. Saxena, et al. 2010;251(2):323-9. PubMed · Publisher

  Abstract

  Background: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are treatment approaches for peritoneal carcinomatosis that has demonstrated improved survival outcomes with acceptable complication rates. This report aims to measure and describe the survival outcomes and health care cost associated with CRS and HIPEC for peritoneal surface malignancies at a centralized tertiary institution in Australia.

  Methods: The expenditure of treatment for 136 consecutive patients who underwent 159 CRS and HIPEC from June 2002 to June 2008 were obtained. Together with their survival outcomes from treatment, a cost-effectiveness analysis was performed.

  Results: The average cost of CRS and HIPEC per patient and per life year for appendix cancer is AUD $88,423 (range, AUD $23,933-AUD $299,145) and AUD $37,737/LY; for colorectal cancer is AUD $66,148 (range, AUD $26,079-AUD $409,666) and AUD $29,757/LY; for pseudomyxoma peritonei is AUD $92,308 (range, AUD $11,562-AUD $501,144) and AUD $29,559/LY; for peritoneal mesothelioma is AUD $55,062 (range, AUD $23,261-AUD $94,104) and AUD $20,521/LY; and for other peritoneal surface malignancies is AUD $44,668 (range, AUD $31,592-AUD $70,026) and AUD $22,091/LY.

  Conclusions: This complex surgical treatment results in significant increases in medical costs with a parallel increase in survival for a disease that has been poorly treated, and hence may be considered as cost-effective given the observed life years gained.

1940s

• Morbidity and Mortality in Talc Granuloma: Report of a Fatal Case. A.J. Swingle. 1948;128(1):144-52. PubMed · Publisher · Free full text

Browse every journal in the library or the library by type of article, or return to medical research.